Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial

ZA Wainberg; K Shitara; E Van Cutsem; L Wyrwicz; KW Lee; I Kudaba; M Garrido; HCC Chung; J Lee; HR Castro-Salguero; W Mansoor; MI Braghiroli; N Karaseva; E Goekkurt; H Satake; J Chao; U Kher; S Shah; P Bhagia; J Tabernero

doi:10.1200/JCO.2022.40.4_suppl.243

Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial

ZA Wainberg, K Shitara, E Van Cutsem, L Wyrwicz, KW Lee, I Kudaba, M Garrido, HCC Chung, J Lee, HR Castro-Salguero, W Mansoor, MI Braghiroli, N Karaseva, E Goekkurt, H Satake, J Chao, U Kher, S Shah, P Bhagia, J Tabernero

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	243
Journal	Journal of Clinical Oncology
Volume	40
Issue number	4, Suppl.
DOIs	https://doi.org/10.1200/JCO.2022.40.4_suppl.243
Publication status	Published - 1 Feb 2022
Externally published	Yes
Event	ASCO Gastrointestinal Cancers Symposium 2022 - San Francisco, United States Duration: 20 Jan 2022 → 22 Jan 2022 https://meetings.asco.org/meetings/2022-gastrointestinal-cancers-symposium/286/program-guide/scheduled-sessions

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

10.1200/JCO.2022.40.4_suppl.243

Cite this

Wainberg, ZA., Shitara, K., Van Cutsem, E., Wyrwicz, L., Lee, KW., Kudaba, I., Garrido, M., Chung, HCC., Lee, J., Castro-Salguero, HR., Mansoor, W., Braghiroli, MI., Karaseva, N., Goekkurt, E., Satake, H., Chao, J., Kher, U., Shah, S., Bhagia, P., & Tabernero, J. (2022). Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial. Journal of Clinical Oncology, 40(4, Suppl.), Article 243. https://doi.org/10.1200/JCO.2022.40.4_suppl.243

@article{eb7d83e12ab7431ea0e67855eca6c5d7,

title = "Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial",

author = "ZA Wainberg and K Shitara and {Van Cutsem}, E and L Wyrwicz and KW Lee and I Kudaba and M Garrido and HCC Chung and J Lee and HR Castro-Salguero and W Mansoor and MI Braghiroli and N Karaseva and E Goekkurt and H Satake and J Chao and U Kher and S Shah and P Bhagia and J Tabernero",

year = "2022",

month = feb,

day = "1",

doi = "10.1200/JCO.2022.40.4_suppl.243",

language = "English",

volume = "40",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "4, Suppl.",

note = "ASCO Gastrointestinal Cancers Symposium 2022 ; Conference date: 20-01-2022 Through 22-01-2022",

url = "https://meetings.asco.org/meetings/2022-gastrointestinal-cancers-symposium/286/program-guide/scheduled-sessions",

}

Wainberg, ZA, Shitara, K, Van Cutsem, E, Wyrwicz, L, Lee, KW, Kudaba, I, Garrido, M, Chung, HCC, Lee, J, Castro-Salguero, HR, Mansoor, W, Braghiroli, MI, Karaseva, N, Goekkurt, E, Satake, H, Chao, J, Kher, U, Shah, S, Bhagia, P & Tabernero, J 2022, 'Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial', Journal of Clinical Oncology, vol. 40, no. 4, Suppl., 243. https://doi.org/10.1200/JCO.2022.40.4_suppl.243

Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial. / Wainberg, ZA; Shitara, K; Van Cutsem, E et al.
In: Journal of Clinical Oncology, Vol. 40, No. 4, Suppl., 243, 01.02.2022.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma

T2 - ASCO Gastrointestinal Cancers Symposium 2022

AU - Wainberg, ZA

AU - Shitara, K

AU - Van Cutsem, E

AU - Wyrwicz, L

AU - Lee, KW

AU - Kudaba, I

AU - Garrido, M

AU - Chung, HCC

AU - Lee, J

AU - Castro-Salguero, HR

AU - Mansoor, W

AU - Braghiroli, MI

AU - Karaseva, N

AU - Goekkurt, E

AU - Satake, H

AU - Chao, J

AU - Kher, U

AU - Shah, S

AU - Bhagia, P

AU - Tabernero, J

PY - 2022/2/1

Y1 - 2022/2/1

UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/WOS:000770995900237

U2 - 10.1200/JCO.2022.40.4_suppl.243

DO - 10.1200/JCO.2022.40.4_suppl.243

M3 - Meeting Abstract

SN - 0732-183X

VL - 40

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 4, Suppl.

M1 - 243

Y2 - 20 January 2022 through 22 January 2022

ER -

Wainberg ZA, Shitara K, Van Cutsem E, Wyrwicz L, Lee KW, Kudaba I et al. Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial. Journal of Clinical Oncology. 2022 Feb 1;40(4, Suppl.):243. doi: 10.1200/JCO.2022.40.4_suppl.243

Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this